<--- Back to Details
First PageDocument Content
Clinical research / Pharmaceutical industry / Clinical pharmacology / Center for Drug Evaluation and Research / Prescription Drug User Fee Act / Drug development / FDA Fast Track Development Program / New Drug Application / Drug discovery / Pharmaceutical sciences / Food and Drug Administration / Pharmacology
Clinical research
Pharmaceutical industry
Clinical pharmacology
Center for Drug Evaluation and Research
Prescription Drug User Fee Act
Drug development
FDA Fast Track Development Program
New Drug Application
Drug discovery
Pharmaceutical sciences
Food and Drug Administration
Pharmacology

APPROVED DRUGS[removed]Adempas Anoro Ellipta

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 2,99 MB

Share Document on Facebook

Similar Documents

Capital Reporting Company Public Meeting on PDUFA VIU.S. FOOD & DRUG ADMINISTRATION PRESCRIPTION DRUG USER FEE ACT

DocID: 1t0K4 - View Document

Prescription Drug User Fee Act (PDUFA) Reauthorization Public Meeting August 15, 2016 1 Basic PDUFA Construct

DocID: 1sUEh - View Document

Prescription Drug User Fee Act (PDUFA) Reauthorization August 15, 2016 Page 1 1 FOOD AND DRUG ADMINISTRATION (FDA)

DocID: 1sUz3 - View Document

Health / Pharmaceutical sciences / Pharmaceutical industry / Food and Drug Administration / Advertising / Direct-to-consumer advertising / Unnecessary health care / Prescription Drug User Fee Act / Criticism of the Food and Drug Administration

United States Government Accountability Office GAO Testimony Before the Subcommittee on Oversight

DocID: 1rfHg - View Document

Health / Pharmaceuticals policy / Food and Drug Administration / Medical research / Names / Healthcare quality / Patient safety / United States Adopted Name / Prescription Drug User Fee Act / Over-the-counter drug / Medical prescription / International nonproprietary name

Best Practices in Developing Proprietary Names for Drugs

DocID: 1r8R5 - View Document